These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 29254534

  • 21. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
    Hannun P, Felipe C, Ferreira A, Sandes-Freitas T, Cristelli M, Aguiar W, Franco M, Campos E, Gerbase de Lima M, Tedesco-Silva H, Medina-Pestana J.
    Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
    [Abstract] [Full Text] [Related]

  • 22. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
    Nanmoku K, Kurosawa A, Kubo T, Shinzato T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
    [Abstract] [Full Text] [Related]

  • 23. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L, Noble J, Terrec F, Bennani HN, Chevallier E, Janbon B, Germi R, Bugnazet M, Imerzoukene F, Malvezzi P, Rostaing L, Jouve T.
    Int Urol Nephrol; 2021 Mar; 53(3):591-600. PubMed ID: 33058036
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
    Felipe CR, Oliveira NI, Hannun PG, de Paula MI, Tedesco-Silva H, Medina-Pestana JO.
    Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
    [Abstract] [Full Text] [Related]

  • 25. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
    Narumi S, Watarai Y, Goto N, Hiramitsu T, Tsujita M, Okada M, Futamura K, Tomosugi T, Nishihira M, Sakamoto S, Kobayashi T.
    Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
    [Abstract] [Full Text] [Related]

  • 26. Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation.
    Young M, Plosker GL.
    Pharmacoeconomics; 2002 Jun; 20(10):675-713. PubMed ID: 12162756
    [Abstract] [Full Text] [Related]

  • 27. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Jun; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 28. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [Abstract] [Full Text] [Related]

  • 29. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J, Kamar N, Mengelle C, Allal A, Sallusto F, Doumerc N, Game X, Congy-Jolivet N, Esposito L, Debiol B, Rostaing L.
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [Abstract] [Full Text] [Related]

  • 30. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 31. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 32. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
    Okabe Y, Noguchi H, Sato Y, Mei T, Kaku K, Ueki K, Tsuchimoto A, Nakamura M.
    Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
    [Abstract] [Full Text] [Related]

  • 33. Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial.
    Kaminski H, Kamar N, Thaunat O, Bouvier N, Caillard S, Garrigue I, Anglicheau D, Rérolle JP, Le Meur Y, Durrbach A, Bachelet T, Savel H, Coueron R, Visentin J, Del Bello A, Pellegrin I, Déchanet-Merville J, Merville P, Thiébaut R, Couzi L.
    Am J Transplant; 2022 May; 22(5):1430-1441. PubMed ID: 34990047
    [Abstract] [Full Text] [Related]

  • 34. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 35. Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation.
    Sageshima J, Ciancio G, Chen L, Dohi T, El-Hinnawi A, Paloyo S, Misawa R, Ekwenna O, Yatawatta A, Burke GW.
    Clin Transplant; 2014 Jul; 28(7):797-801. PubMed ID: 24779669
    [Abstract] [Full Text] [Related]

  • 36. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.
    Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS.
    Am J Transplant; 2011 Nov; 11(11):2453-62. PubMed ID: 21812923
    [Abstract] [Full Text] [Related]

  • 37. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group.
    N Engl J Med; 2006 Nov 09; 355(19):1967-77. PubMed ID: 17093248
    [Abstract] [Full Text] [Related]

  • 38. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.
    Pharmacotherapy; 2011 Jun 09; 31(6):566-73. PubMed ID: 21923440
    [Abstract] [Full Text] [Related]

  • 39. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
    Hauser IA, Marx S, Sommerer C, Suwelack B, Dragun D, Witzke O, Lehner F, Schiedel C, Porstner M, Thaiss F, Neudörfl C, Falk CS, Nashan B, Sester M.
    Eur J Immunol; 2021 Apr 09; 51(4):943-955. PubMed ID: 33306229
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients.
    Pennington CA, Tischer SM, Lee E, Lee S, Sindelar J, Park JM.
    Pharmacotherapy; 2015 Aug 09; 35(8):748-54. PubMed ID: 26234282
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.